Investigation of the Effect of Oral Powder Enriched with Curcumin and Probiotics on Cardiometabolic Indices of Patients with Metabolic Syndrome

Determination of the Effect of Functional Oral Powder Enriched with Curcumin, Probiotics, and their Combination on Cardiometabolic Indices in Patients with Metabolic Syndrome with Overweight or Obesity: a Randomized, Double-blinded, Controlled Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220315054290N2

Enrollment

124

Registered

2022-12-07

Start date

2022-12-22

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome. Metabolic syndrome

Interventions

Intervention 1: The first intervention group will receive a daily oral powder enriched with 1 gram of curcumin for 8 weeks. Curcumin powder will be supplied by Karen Company. Intervention 2: The secon

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age: 30-60 years old Metabolic syndrome patients are diagnosed based on the Adult Treatment Panel III (ATP III) criterion Consent to participate in the study

Exclusion criteria

Exclusion criteria: Pregnancy Lactation Metabolic, endocrine, and cardiovascular diseases except diabetes, dyslipidemia, and hypertension

Design outcomes

Primary

Measure	Time frame
Castelli Risk Index I. Timepoint: Before the study and 8 weeks after the start of the study. Method of measurement: Castelli risk index I = TC/HDL - C.;Castelli Risk Index II. Timepoint: Before the study and 8 weeks after the start of the study. Method of measurement: Castelli risk index II = LDL - C/HDL - C.;Atherogenic Index of Plasma (AIP). Timepoint: Before the study and 8 weeks after the start of the study. Method of measurement: AIP = log (TG/HDL - C).;Atherogenic Coefficient = AC. Timepoint: Before the study and 8 weeks after the start of the study. Method of measurement: AC = (TC - HDL - C)/HDL - C.	—

Measure

Time frame

Castelli Risk Index I. Timepoint: Before the study and 8 weeks after the start of the study. Method of measurement: Castelli risk index I = TC/HDL - C.;Castelli Risk Index II. Timepoint: Before the study and 8 weeks after the start of the study. Method of measurement: Castelli risk index II = LDL - C/HDL - C.;Atherogenic Index of Plasma (AIP). Timepoint: Before the study and 8 weeks after the start of the study. Method of measurement: AIP = log (TG/HDL - C).;Atherogenic Coefficient = AC. Timepoint: Before the study and 8 weeks after the start of the study. Method of measurement: AC = (TC - HDL - C)/HDL - C.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Mohammadi

Shiraz University of Medical Sciences

mohamadyfa@sums.ac.ir+98 71 3725 8099

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026